The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 8691231 B1

PDF
Full Text
Expired
Date of Patent:
Apr. 08, 2014

Filed:

Jun. 04, 2012
Applicants:

Raghida Bukhalid, Melrose, MA (US);

Ulrik Nielsen, Quincy, MA (US);

Shannon Werner, Belmont, MA (US);

Jeffrey David Kearns, Arlington, MA (US);

Inventors:

Raghida Bukhalid, Melrose, MA (US);

Ulrik Nielsen, Quincy, MA (US);

Shannon Werner, Belmont, MA (US);

Jeffrey David Kearns, Arlington, MA (US);

Assignee:

Merrimack Pharmaceuticals, Inc., Cambridge, MA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); G01N 33/567 (2006.01); A61K 38/18 (2006.01); A61P 35/00 (2006.01);
U.S. Cl.
CPC ...
Abstract

Disclosed are pharmaceutical preparations for, and methods for determining, appropriate and effective treatment with therapeutic agents comprising a single species of anti-EGFR monoclonal antibody or therapeutic agents comprising a plurality of species of such antibodies, as well as kits useful for making such determinations.


Find Patent Forward Citations

Quick Actions:

Bukhalid, Raghida. (2014). Methods of treatment of tumors expressing predominantly high affinity egfr ligands or tumors expressing predominantly low affinity egfr ligands with monoclonal and oligoclonal anti-egfr antibodies (U.S. Patent No. 8691231). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/8691231

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…